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Abstract: Oxaliplatin-based chemotherapy improves the outcomes of metastatic colorectal 
cancer patients. Its most significant and dose-limiting side effect is the development of  
a neuropathic syndrome. The mechanism of the neurotoxicity is unclear. The limited 
knowledge about differences existing between neurotoxic and antitumor effects hinders the 
discovery of effective and safe adjuvant therapies. In vitro, we suggested cell-specific 
activation apoptotic pathways in normal nervous cells (astrocytes) vs. colon-cancer cells 
(HT-29). In the present research we compared the apoptotic signals evoked by oxaliplatin 
in astrocytes and HT-29 analyzing the intrinsic and extrinsic apoptotic pathways. In 
astrocytes, oxaliplatin induced a mitochondrial derangement measured as cytosolic release of 
cytochrome C, increase in superoxide anion levels and decreased expression of the 
antiapoptotic protein Bcl-2. Caspase-8, a main initiator of the extrinsic process remained 
unaltered. On the contrary, in HT-29 oxaliplatin increased caspase-8 activity and Bid 
expression, thus activating the extrinsic apoptosis, while the Bcl-2 increased expression 
blocked the mitochondrial damage. Data suggest the preferred activation of the intrinsic 
apoptosis as oxaliplatin damage signaling in normal nervous cells. The extrinsic pathway 
prevails in tumor cells indicating a possible strategy for planning new molecules to treat 
oxaliplatin-dependent neurotoxicity without negatively influence chemotherapy. 
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1. Introduction 
Oxaliplatin was successfully introduced for the management of advanced colorectal cancer, the 
second leading cause of cancer death in Western countries [1,2]. This antineoplastic agent differs from 
previous platinum compounds for the configuration of the amino substituents [3,4] and, characteristically, 
its major dose-limiting side effect is neurotoxicity that leads to the development of peripheral 
neuropathy [5,6]. The poor knowledge about the mechanisms of oxaliplatin neurotoxicity limits the 
development of effective adjuvant therapies thus making chemotherapy-induced neuropathies an 
unmet medical need. Moreover, the pharmacological approach is complicated by the fundamental 
necessity to not interfere with the antitumoral effects. 
Recently, we highlighted the redox unbalance as a target for the management of oxaliplatin 
neurotoxicity, and the natural antioxidant compound silibinin was suggested to prevent nervous 
damage and pain in a rat model of oxaliplatin neuropathy [7,8]. In a cellular model of  
oxaliplatin-neurotoxicity (primary astrocyte cell culture), silibinin, as well as α-tocopherol, exerted 
cytoprotective properties reducing the oxidative damage and limiting the activation of caspase-3, the 
downstream effector of apoptotic processes [9]. Interestingly, antioxidants were unable to reduce 
caspase-3 activation induced by oxaliplatin in the human adenocarcinoma colorectal cancer cell line 
HT-29 [9]. The different effect observed in astrocytes and in HT-29 lead us to hypothesize that 
oxaliplatin may evoke distinct apoptotic signals in normal vs. tumoral cells. On the other hand, the 
intrinsic and the extrinsic apoptotic pathways mediated by a mitochondrial derangement and by death 
receptors, respectively, have as common effector caspase 3 [10,11]. 
Aimed to individuate new and specific biological targets for the treatment of oxaliplatin 
neurotoxicity, specific markers of the two apoptotic pathways (extensively reviewed in [12]) were 
studied in primary cultured astrocytes in comparison with HT-29 cells. In particular, the mitochondrial 
dysfunction was studied by measuring the release of cytochrome C from mitochondria to the cytosol, 
the superoxide anion (O2.−) levels [13–15] and the expression of the antiapoptotic protein Bcl-2 [16]. 
Moreover, the protein expression levels were evaluated for the initiator of the extrinsic apoptotic 
process death receptor 5 (DR5) [17,18] and Bid, pro-apoptotic protein activated by caspase-8 and able 
to transfer the apoptotic information to the intrinsic process [19]. Finally, the activation of caspase-8, 
central hallmark of the extrinsic pathway was measured [11,20]. 
2. Results 
Aimed to evaluate the regulation of the apoptotic processes mediated by oxaliplatin, specific 
effectors of the intrinsic and extrinsic apoptotic pathways were measured in primary rat astrocytes in 
comparison to HT-29 cells. Oxaliplatin concentration was chosen on the basis of previous published 
data [9]. Moreover, the comparison of astrocyte and HT-29 cell viability, after 24 h incubation with 
increasing concentrations of oxaliplatin, revealed a similar response in the different cell types 
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(Supplementary Material, Table S1). The treatment with oxaliplatin 100 µM for 8 h did not alter cell 
viability, whereas is allows observing increased caspase-3 activity in astrocytes as well as in HT-29. 
The pro-apoptotic effect of oxaliplatin was comparable in both cell types [9]. 
In astrocytes, 8 h incubation with 100 µM oxaliplatin, affected mitochondrial functionality.  
The immunolabeling of cytochrome C displayed a punctuate staining in control condition that evolved 
in a diffuse cytosolic pattern after oxaliplatin treatment (Figure 1). 
 
Figure 1. Cytosolic release of cytochrome C. Astrocytes (5 × 104 cells/slide) and HT-29  
(5 × 104 cells/slide) were exposed to 100 μM oxaliplatin for 8 h. Specimens were  
stained with anti-cytochrome C and a secondary antibody conjugated with Alexa Fluor 488 
(green) and DAPI (blue) for nucleus visualization. (A1–A3) control astrocytes; (B1–B3)  
oxaliplatin-treated astrocytes; (C1–C3) control HT-29; (D1–D3) oxaliplatin-treated HT-29. 
Calibration: 20 µm. Bars represent the mean ± S.E.M of cells displaying a diffuse cytosolic 
distribution of cytochrome C as percentage of total analyzed cells. Cells were counted using 
the “cell counter” plugin of ImageJ 1.33, free-share image analysis software (ImageJ, NIH, 
Bethesda, MD, USA). At least three fields (40X 0.75NA objective) per slide and two slides for 
each condition were analyzed, repeating the experiment three times. ** p < 0.01 vs. control. 
The release of cytochrome C from mitochondria to the cytosol was observed in 197 out of  
247 treated cells and in 21 out of 253 control cells. On the contrary, oxaliplatin (100 µM, 8 h) did not 
alter cytochrome C localization in HT-29 (Figure 1).  
In glial cells the mitochondrial alterations were also highlighted by measuring the redox unbalance. 
Superoxide anion production (O2.−) was increased by oxaliplatin (100 µM, 4 h) by about 1.5 times  
(in comparison to the basal level of control condition, 17.9 ± 0.3 µM/mg protein/4 h; Figure 2). 
Int. J. Mol. Sci. 2015, 16 5389 
 
 
In HT-29 cells, the chemotherapic agent did not induce any increase in superoxide anion level as 
measured in astrocyte cultures. To note, the O2.− basal level in the tumoral cells was significantly 
higher than those detected in the astrocyte cultures (37.8 ± 2.1 µM/mg protein/4 h; Figure 2). 
 
Figure 2. O2.− concentrations. Astrocytes (5 × 105 cells/well) and HT-29 (3 × 105 cells/well) 
were exposed to 100 μM oxaliplatin for 4 h. O2.− concentration was evaluated by cytochrome 
C assay. The nonspecific absorbance was measured in the presence of superoxide 
dismutase (SOD; 300 mU/mL) and subtracted from the total value. Values are expressed as 
µM/mg protein/4 h. Bars represent the mean ± S.E.M. of three experiments. * p < 0.05 vs. 
control and # p < 0.05 vs. astrocytes control. 
Evaluating protein expression by Western blot analysis, in basal conditions Bcl-2 was higher in 
astrocytes as compared to HT-29 (Figure 3). Incubation with oxaliplatin (100 µM, 8 h) reduced at  
about 63% Bcl-2 protein expression in astrocytes, whereas it increased Bcl-2 protein level up to  
145.6% ± 12.1% in HT-29 cells (Figure 3). 
The analysis of extrinsic pathway parameters revealed a selective activation in HT-29 cell culture. 
The incubation (8 h) with 100 µM oxaliplatin did not significantly alter the protein expression of the 
DR5 receptor neither in astrocytes nor in HT-29 (Figure 4). 
We performed experiments aimed to measure caspase-8 activity. As shown in Figure 5, caspase-8 
activity in astrocyte was 132.3 ± 8.9 arbitrary units/mg proteins in control condition and was  
not changed by oxaliplatin. On the contrary, in HT-29 oxaliplatin increased the enzyme activity up  
to 292.9 ± 25.9 arbitrary units/mg proteins from the control condition of 194.5 ± 21.4 arbitrary 
units/mg proteins. 
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Figure 3. Bcl-2 protein expression. Astrocytes (106 cells/flask) and HT-29 (8 × 105 cells/flask) 
were incubated with 100 μM oxaliplatin for 8 h and then cell lysates were analyzed by Western 
blot. Densitometric analysis (top) and representative immunoblot (bottom) are shown. 
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) was used as loading control and 
GAPDH normalization was performed for each sample. Values are expressed as integrated 
density making the ratio between Bcl-2 and GAPDH specific band intensities. Bars represent 
the mean ± S.E.M. of three experiments. * p < 0.05 vs. control, ** p < 0.01 vs. control and  
# p < 0.05 vs. astrocytes control. 
 
Figure 4. Death receptor 5 (DR5) protein expression. Astrocytes (106 cells/flask) and HT-29  
(8 × 105 cells/flask) were incubated with 100 μM oxaliplatin for 8 h and then Western blot 
analysis were performed. Densitometric analysis (top) and representative immunoblot 
(bottom) are shown. GAPDH was used as loading control and GAPDH normalization was 
performed for each sample. Values are expressed as integrated density making the ratio 
between DR5 and GAPDH specific band intensities. Bars represent the mean ± S.E.M. of 
three experiments. 
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Also oxaliplatin increased caspase-8 activity in the rat adrenal pheochromocytoma cell line PC12 
from the control value of 178.6 ± 29.6 arbitrary units/mg proteins to 415.8 ± 28.7 arbitrary units/mg 
proteins (Figure 5). 
 
Figure 5. Caspase-8 activity. Astrocytes (5 × 105 cells/well), HT-29 (3 × 105 cells/well) 
and PC12 (3 × 105 cells/well) were treated with 100 μM oxaliplatin for 8 h. Caspase-8 
activity was expressed as fluorescent arbitrary unit/mg protein. Bars represent the  
mean ± S.E.M. of three experiments. * p < 0.05 vs. control. 
Figure 6 shows protein expression levels of Bid evaluated by Western blot. In HT-29, oxaliplatin  
(100 µM, 8 h) increased Bid by about 70%. In astrocyte cells, Bid was undetectable in control 
condition as well as after oxaliplatin treatment. 
 
Figure 6. Bid protein expression. HT-29 (8 × 105 cells/flask) were incubated with 100 μM 
oxaliplatin for 8 h and then cell lysates were analyzed by Western blot. Densitometric 
analysis (top) and representative immunoblot (bottom) are shown. GAPDH was used as 
loading control and GAPDH normalization was performed for each sample. Values are 
expressed as integrated density making the ratio between Bid and GAPDH specific band 
intensities. Bars represent the mean ± S.E.M. of three experiments. * p < 0.05 vs. control. 
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3. Discussion 
Neuropathic syndrome development is one of the main adverse drug reactions that negatively 
influence the anticancer therapy and drastically reduce the quality of life of the oncologic patients [1,5]. 
The lack of knowledge about the pathological events at the base of the neurodegenerative phenomenon 
is primarily responsible for the limited therapeutic resources. The available symptomatic drugs are 
scarcely effective and the identification of active disease-modifying agents remains the goal of the 
research in this field. On the other hand, the most important feature of antineuropathic agents 
candidate to treat cancer patients, is the lack of interaction with chemotherapies maintaining a full 
effectiveness of the anti-neoplastic potential. A limited knowledge of the distinctions between the 
biological alterations promoted by the anticancer agents in normal nervous cells and in tumor cells 
strongly impairs the development of targeted adjuvant therapies. 
In the present research, the attention has been focused on oxaliplatin, showing that the  
apoptosis-inducing mechanism is preferentially mediated in astrocytes by the intrinsic pathway and by 
the extrinsic in colon cancer cell HT-29. 
The intrinsic pathway is promoted by a mitochondrial alteration characterized by membrane 
potential changes, release of cytochrome C and redox unbalance [21,22]. In normal glial cells, 
oxaliplatin promotes the release of cytochrome C from mitochondria to the cytosol increasing the 
number of cells showing a diffuse immunoreactivity. Accordingly, Zheng et al. [23] described an 
oxaliplatin-mediated increase of swollen and vacuolated mitochondria in peripheral nerve axons of 
neuropathic rats [24]. Mitochondria represent the major source of intracellular ROS, which are  
by-products of oxidative phosphorylation. ROS excess, or the limited counterbalance by endogenous 
antioxidant defenses, may damage lipids, proteins, DNA, and mitochondria itself [24]. Oxidative stress 
can activate the mitochondrial permeability transition pore (mtPTP) creating an open channel across 
the mitochondrial inner and outer membranes which permits the free diffusion of molecules with a 
molecular weight lesser than 1500 Da. The resulting collapse of trans-membrane electrochemical 
gradient and the swelling of mitochondria cause the release of cytochrome C [24,25]. Among other 
ROS, O2.− may directly lead to reduced complex I activity, limiting drastically the metabolic role of the 
organelle [26–28]. In this view, the increased O2.− levels registered in nervous cells treated with 
oxaliplatin [9] and confirmed in the present results, underlines the mitochondrial suffering. 
The extent of the intrinsic pathway activation appears marked in astrocytes since levels of the 
antiapoptotic protein Bcl-2 is reduced after oxaliplatin treatment. Bcl-2 belongs to the Bcl-2 protein 
superfamily composed by anti-apoptotic and pro-apoptotic factors [26]. Bcl-2 is localized on the 
external mitochondrial membrane and prevents the release of pro-apoptotic molecules (such as 
cytochrome C) from the mitochondria to the cytosol [29,30] limiting the voltage dependent anion 
channel formation and the dysregulation of the mitochondrial membrane potential [31,32]. Normally, 
astrocytes express higher steady-state levels of Bcl-2 than neurons [33] suggesting a low vulnerability 
of astrocytes. Furthermore, in astrocytes oxaliplatin does not increase the expression of the  
pro-apoptotic protein Bid (able to activate the intrinsic apoptotic process by inducing the cytosolic 
release of cytochrome C) [34], and Bid basal levels are under the detection threshold. The low basal 
level of Bid in astrocytes agrees with Harrison et al. [33]. 
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Under physiological conditions, glial cells exert neuroprotective effects by providing neurons with 
substrates for oxidation, regulating the levels of neurotoxic molecules like glutamate [35] and free 
radicals [36,37]. The induction of apoptosis, the dysregulation of superoxide anion homeostasis [9], 
and the reduction of Bcl-2 levels in astrocytes suggest that the neurotoxic effects of oxaliplatin derive, 
at least in part, from an impairment of glial neuroprotective activity. 
Caspase-8 is one of the principal initiator of the extrinsic process and directly activates the effector 
caspase-3 [38]. The two major pathways to apoptosis are largely independent, although in certain cell 
types (e.g., hepatocytes) may intersect. Indeed, caspase-8 can process the pro-apoptotic Bid into its 
active truncated form transferring the apoptotic information to the mitochondrial process [39]. On the 
other hand, to prevent catastrophic unscheduled cell death, both pathways are tightly regulated, at 
multiple steps. Present data show that the apoptotic process activated by oxaliplatin in astrocytes is 
completely independent from this apoptotic mediator, whereas the anticancer agent significantly 
increases caspase-8 activity in the human colon cancer cell line HT-29 and rat PC12 cells (ruling out 
the possibility that a species-dependent diversity may influence the results). In HT-29 cells, the 
expression of Bid is increased after oxaliplatin treatment, confirming the activation of the extrinsic 
pathway. Moreover, Bid seems unable to cross-activate the intrinsic process since cytochrome C is not 
significantly released in the cytosol in HT-29. The block of this pathway may be due to the increased 
levels of Bcl-2 able to protect mitochondria functionality. Bcl-2 is considered a potent multidrug 
resistance factor [40]. 
Although ROS can play a role in oxaliplatin-induced apoptosis of human renal cancer cells [41], 
O2.− production is not modified by oxaliplatin in HT-29. These human adenocarcinoma cell line shows 
a basal O2.− production higher than astrocytes, suggesting that these tumoral cells are less susceptible 
to the oxidative toxic effect and can therefore survive in the presence of high ROS concentrations. 
The faster catabolism of cancer cells is lesser sustained by mitochondria in comparison to normal 
non-neoplastic cells [42]. Tumor cells may produce energy by a high rate of glycolysis followed by 
lactic acid fermentation in the cytosol. On the contrary, normal cells show a comparatively low rate of 
glycolysis followed by oxidation of pyruvate in mitochondria. Since glycolysis provides most of the 
building blocks required for cell proliferation, cancer cells need to activate glycolysis [43]. A lesser 
sensitivity of the mitochondria functionality against oxaliplatin toxicity in HT-29 in comparison to 
astrocytes is suggested. 
4. Experimental Section 
4.1. Cell Cultures 
The human colon cancer cell lines HT-29 and the rat adrenal pheochromocytoma cell line PC12 
were obtained from American Type Culture Collection (Rockville, MD, USA). HT-29 were cultured in 
DMEM high glucose (Invitrogen, Milan, Italy, 11965-092) and PC12 in RMPI 1640 (Invitrogen,  
11875-085). Medium for HT-29 was supplemented with 10% FBS, 2 mM L-glutamine, 100 IU·mL−1 
penicillin and 100 μg·mL−1 streptomycin (Sigma-Aldrich, Milan, Italy, S6501). Medium for PC12 
cells was supplemented with 5% FBS, 10% horse serum, 100 IU·mL−1 penicillin and 100 μg·mL−1 
streptomycin (Sigma-Aldrich, S6501). Cells were maintained at 37 °C and 5% CO2 atmosphere. 
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Primary cultures of astrocytes were obtained according to the method described by McCarthy and  
de Vellis [44]. Briefly, the cerebral cortex of newborn (P1–P3) Sprague-Dawley rats (Harlan, Padova, 
Italy) were dissociated in Hanks’ balanced salt solution containing 0.5% trypsin/EDTA and 1% DNase 
(Sigma-Aldrich, T4174 and D4527) for 30 min at 37 °C. The suspension was mechanically 
homogenized and filtered. Cells were plated in high-glucose DMEM with 10% FBS. Confluent 
primary glial cultures were used to isolate astrocytes, removing microglia and oligodendrocytes by 
shaking. Immunocytochemistry analysis with GFAP staining revealed the purity of astrocyte cultures. 
Cells were fixed in 4% paraformaldehyde, then incubated with the antibody (Dako, Glostrup, Denmark, 
Z033429, 1:500), and visualized using Alexa Fluor-conjugated secondary antibody (Invitrogen, Milan, 
Italy, #A11034, 1:500). Nuclei were stained with 4,6-diamidino-2-phenylindole dihydrochloride.  
GFAP-positive cells were 90% in astrocyte cultures. Astrocytes were plated, according to the 
experimental needs, 21 days after cell isolation. Formal approval to conduct the experiments described 
was obtained from the Animal Subjects Review Board of the University of Florence. The ethics policy 
of the University of Florence complies with the Guide for the Care and Use of Laboratory Animals of 
the U.S. National Institutes of Health (NIH Publication No. 85-23, revised 1996; University of 
Florence Assurance No. A5278-01). 
HT-29, PC12 and astrocyte cells were starved in serum-free DMEM overnight before all treatments. 
Protein concentrations were measured by bicinchoninc acid assay (Sigma-Aldrich, for Bicinchoninic 
Acid Solution B9643, for Copper sulphate solution C2284). 
Oxaliplatin (Sequoia Research Products, Pangbourne, UK), concentrations and times of incubation 
were chosen on the basis of previously performed evaluations [9]. 
4.2. Cytochrome C Cytosolic Release 
Astrocytes or HT-29 cells were plated in D-polylisinated slides (105 cells/slide) and 48 h after  
were incubated with 100 μM oxaliplatin for 8 h. After treatment, the cells were fixed with 4% 
paraformaldehyde in PBS, permeabilized for 10 min with PBS containing 0.1% Triton X-100, blocked 
with PBS containing albumin 1% (Sigma-Aldrich, A2153) and incubated overnight with a rabbit  
anti-cytochrome C antibody at 4 °C (Santa Cruz Biotechnology, Dallas, TX, USA, sc-7159, 1:300). 
Slides were washed three times with PBS and incubated with the appropriate secondary antibody 
labeled with Alexa Fluor 488 (Invitrogen, #A11034, 1:500) at room temperature for 1 h. Images were 
acquired by a motorized Leica DM6000B microscope equipped with a DFC350FX camera (Leica, 
Lawrenceville, GA, USA). Cytochrome C cytosolic levels were assessed by inspection of at least  
three fields (40X 0.75NA objective) per slide; two slides for each condition were analyzed. Cells 
displaying a diffuse cytosolic staining pattern were counted using the “cell counter” plugin of ImageJ 
(1.33 free-share image analysis software, ImageJ, NIH, Bethesda, MD, USA). Results were expressed 
as percentage of cells displaying a diffuse (released) distribution of cytochrome C [45,46]. 
4.3. Superoxide Dismutase (SOD)-Inhibitable Superoxide Anion (O2.−) Levels 
Astrocytes and HT-29 cells were plated in six-well plates (5 × 105 cells/well for astrocytes and  
3 × 105 cells/well for HT-29) and, 48 h after, they were incubated with or without 100 μM oxaliplatin 
in serum-free DMEM containing cytochrome C from bovine heart (Sigma-Aldrich, C2037, 1 mg/mL) 
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for 4 h at 37 °C. Non-specific cytochrome C reduction was evaluated by carrying out tests in the 
presence of bovine SOD (Sigma-Aldrich, S9697, 300 mU/mL). The supernatants were collected, and the 
optical density was spectrophotometrically measured at 550 nm. After subtracting the non-specific 
absorbance, the SOD-inhibitable O2.− amount was calculated by using an extinction coefficient of  
2.1 × 104 M−1·cm−1 and expressed as µM/mg proteins/4 h. The 4 h incubation interval was chosen on the 
basis of preliminary experiments, which showed poor reliability for longer cytochrome C exposure to the 
cellular environment. 
4.4. Western Blot Analysis 
Astrocytes or HT-29 cells were plated in 25 cm2 cell culture flasks (106 cells/flask), grown for 48 h 
and incubated with 100 μM oxaliplatin for 8 h. After treatment, the cells were homogenized in lysis 
buffer containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 0.5% Triton X-100, 
Complete Protease Inhibitor (Roche, Milan, Italy, 04693124001), and the homogenate was incubated 
on ice for 30 min. The suspension was sonicated on ice for 15 s. After centrifugation (13,000× g for  
15 min at 4 °C), aliquots containing 35 μg total proteins were separated on a 4%–12% sodium dodecyl 
sulfate (SDS)-polyacrylamide gel by electrophoresis and transferred onto nitrocellulose membranes. 
Membranes were blocked with 5% nonfat dry milk in PBS containing 0.1% Tween 20 (PBST) and 
then probed overnight with specific primary antibodies. Goat anti-DR5 receptor antibody (Santa Cruz 
Biotechnology, sc-19529), rabbit anti Bcl-2 antibody (Cell Signaling, Milan, Italy, #2876) and rabbit 
anti Bid antibody (Santa Cruz Biotechnology, sc-11423) were diluted to 1:500, 1:1000 and 1:1000, 
respectively, in 5% nonfat dry milk in PBST. Membranes were washed with PBST and incubated for  
1 h in PBST containing the appropriate horseradish peroxidase-conjugated secondary antibody (anti 
rabbit Cell Signaling, #7074, 1:5000; anti goat Santa Cruz Biotechnology, sc-2020, 1:5000). ECL 
(Enhanced chemiluminescence; Pierce, Milan, Italy, 32106) was used to visualize the peroxidase-coated 
bands. Densitometric analysis was performed using the ‘‘ImageJ” analysis software (ImageJ, NIH) and 
results were normalized to GAPDH (Cell signaling, #2118, 1:2000) immunoreactivity as internal control. 
Values were reported as percentages in comparison to control, which was arbitrarily fixed at 100%. 
4.5. Caspase-8 Activity 
Astrocytes, HT-29 and PC12 cells were plated in six-well plates (5 × 105 cells/well for astrocytes 
and 3 × 105 cells/well for HT-29 and PC12) and, after 48 h, they were incubated with 100 μM 
oxaliplatin for 8 h. After treatment, cells were scraped with 70 µL of lysis buffer as suggested by the 
manufacturer (Molecular Probes, Milan, Italy). Fifty microliters of the supernatant were incubated 
with 50 µM of the specific fluorogenic peptide caspase-8 substrate (IETD-AFC composed by  
7-amino-4-trifluoromethyl coumarin and a synthetic tetrapeptide Ile-Glu-Thr-Asp) at 25 °C for 30 min. 
The amount of cleaved substrate in each sample was measured in a 96 well plate fluorescence 
spectrometer (Flexi Station III, Molecular Devices, Sunnyvale, CA, USA; excitation at 400 nm and 
emission at 505 nm). 
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4.6. Statistical Analysis 
Results were expressed as mean ± SEM and analysis of variance (ANOVA) was performed.  
A Bonferroni’s significant difference procedure was used as post hoc comparison. All assessments 
were made by researchers blinded to cell treatments. Data were analyzed using the “Origin 8.1” 
software (OriginLab, Northampton, MA, USA). 
5. Conclusions  
Taken together the present data underline that oxaliplatin-dependent apoptosis is mediated 
preferentially by the intrinsic apoptosis pathway in nervous normal cells. The extrinsic pathway based on 
caspase-8 activation strongly participates to apoptosis phenomena in tumor cells. New neuroprotective 
agents able to preserve mitochondrial functionality without interfere with caspase-8 activation are 
suggested as safe candidate to treat oxaliplatin-dependent neurotoxicity. 
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